NanoViricides Inc. (NNVC)

[changes_iv]

Excerpt from Today's PR...keeping an eye on the prize

NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University’s Fuqua Business School

WEST HAVEN, Conn.--(BUSINESS WIRE)--

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its stock began trading today on the NYSE MKT National Exchange under its original symbol, NNVC.

In another Company news, our CEO, Eugene Seymour, MD, MPH, is invited to speak at the Duke University Fuqua School of Business today afternoon. His talk will focus on policies that can help accelerate the development of pharmaceuticals against diseases that pharma companies would otherwise not have much interest in, or “orphan drug” development.

The concept of the Priority Review Voucher (PRV) was initially developed by three professors, David Ridley, Jeff Moe and Henry Grabowski at the Fuqua School of Business of the Duke University. Dr. Ridley invited Dr. Seymour to speak on the importance of economic incentives to help innovative pharmaceutical companies attach higher priorities to drug development programs against “orphan” diseases.

The Priority Review Voucher concept that the professors developed was embraced by the US FDA. Currently, the US FDA’s list of diseases for which no adequate therapy exists that are eligible for a PRV contains about 16 diseases. Dengue is at present the only viral disease on the list. The existence of the PRV was an important factor in the Company’s decision to assign a high priority to its dengue drug development program.

source: http://finance.yahoo.com/news/nanoviricides-begins-trading-nyse-mkt-133500014.html

In addition to the incentives related to orphan drug status, the Company may be eligible to receive a Priority Review Voucher (PRV) in the USA, upon approval of a drug against dengue viruses. A PRV can be applied by the Company to another drug candidate to obtain a “priority review” to speed up the regulatory process for that other drug. A PRV can also potentially be sold to another pharmaceutical company to obtain an immediate financial benefit. The value of a PRV has been variously estimated to be between $200M to $600M for such transactions.

We have "good news" coming, here and abroad!